Bicycle Therapeutics (BCYC) Expected to Announce Earnings on Thursday

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) is anticipated to post its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Bicycle Therapeutics to post earnings of ($1.05) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 7:00 AM ET.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.95) by ($0.19). The business had revenue of $2.90 million during the quarter, compared to analysts' expectations of $9.43 million. Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%. On average, analysts expect Bicycle Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bicycle Therapeutics Trading Down 4.9%

Shares of Bicycle Therapeutics stock opened at $7.88 on Thursday. Bicycle Therapeutics has a 12-month low of $6.10 and a 12-month high of $26.57. The company has a market cap of $546.16 million, a P/E ratio of -2.25 and a beta of 1.47. The company's fifty day simple moving average is $7.53 and its two-hundred day simple moving average is $7.79.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Oppenheimer reiterated an "outperform" rating and set a $44.00 price target (down previously from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Bicycle Therapeutics in a report on Tuesday, October 14th. Royal Bank Of Canada set a $27.00 target price on Bicycle Therapeutics and gave the stock an "outperform" rating in a research report on Monday, August 11th. Morgan Stanley dropped their price target on Bicycle Therapeutics from $17.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, August 12th. Finally, JMP Securities reduced their price target on Bicycle Therapeutics from $22.00 to $10.00 and set a "market outperform" rating on the stock in a research note on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.22.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the business's stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total value of $27,172.71. Following the sale, the chief executive officer directly owned 475,310 shares of the company's stock, valued at approximately $3,997,357.10. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 8,527 shares of company stock worth $71,738 in the last three months. 22.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Rangeley Capital LLC bought a new stake in Bicycle Therapeutics during the 2nd quarter valued at about $521,000. Moore Capital Management LP increased its position in shares of Bicycle Therapeutics by 50.0% during the second quarter. Moore Capital Management LP now owns 75,000 shares of the company's stock valued at $521,000 after acquiring an additional 25,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in Bicycle Therapeutics by 89.0% in the 2nd quarter. Geode Capital Management LLC now owns 40,412 shares of the company's stock worth $281,000 after acquiring an additional 19,035 shares during the last quarter. Paloma Partners Management Co bought a new position in Bicycle Therapeutics in the 2nd quarter valued at approximately $273,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Bicycle Therapeutics during the 1st quarter valued at $214,000. Institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.